New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2013
20:23 EDTALXN, RHHBYAlexion's price may be more than Roche would be willing to pay, Reuters says
A Roche (RHHBY) bid for Alexion (ALXN) would mark an attempt by Roche to diversify beyond its core cancer competencies through acquisitions but Alexion's valuation may be more than Roche would be willing to pay, says Reuters. Reference Link
News For ALXN;RHHBY From The Last 14 Days
Check below for free stories on ALXN;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 20, 2014
15:43 EDTRHHBYInterMune reports MOU in connection with consolidated Delaware action
Subscribe for More Information
September 17, 2014
11:00 EDTRHHBYRoche CEO rules out megadeals, focused on bolt-on acquisitions, WSJ says
Roche CEO Severin Schwan said the company won't change its acquisition strategy following the recent deals made or abandoned in the pharmaceutical sector, reports the Wall Street Journal. In an interview with WSJ, Shwan said, "We have been very consistent in our approach to M&A." Regarding transformational deal-making, he said, "We have no intention to do that, whatever happens in the industry." Reference Link
07:43 EDTRHHBYBofA/Merrill to hold a conference
Subscribe for More Information
07:34 EDTALXNAlexion names Hallal COO, Carmichael Chief Human Resources Officer
Subscribe for More Information
07:33 EDTALXNAlexion names Hallal COO, Carmichael Chief Human Resources Officer
September 16, 2014
07:31 EDTRHHBYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 14, 2014
17:44 EDTALXNAlexion presents data on pediatric HPP patients treated with asfotase alfa
Alexion Pharmaceuticals announced that researchers presented new data from an integrated analysis of survival from two open-label, Phase 2 studies of asfotase alfa in pediatric patients with hypophosphatasia, HPP, compared with data from a retrospective natural history study of untreated historical control patients matched for age and disease severity. In this analysis, survival in patients with HPP at high risk of death who were treated with asfotase alfa for up to five years was significantly improved compared with untreated historical control patients.These late-breaking results were presented at the American Society for Bone and Mineral Research, ASBMR, 2014 Annual Meeting in Houston, where researchers also presented new data from the ongoing open-label extension phases of two Phase 2 clinical studies in which sustained gains in physical function and reductions in disability and pain were observed in pediatric patients receiving asfotase alfa treatment for up to three years.
September 12, 2014
07:14 EDTALXNAmerican Society for Bone & Mineral Research holds annual meeting
Subscribe for More Information
September 10, 2014
13:04 EDTRHHBYRoche unit receives orphan status for lung cancer mutation drug
Subscribe for More Information
September 8, 2014
07:15 EDTRHHBYIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
06:31 EDTALXNAlexion announces asfotase alfa granted orphan drug designation in Japan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use